Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 12/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nedocromil SCHEMBL4611 | 1.00 | PDE5A (0.47) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL2879046 | 0.99 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL20481863 | 0.99 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL28341341 | 0.99 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL24943 | 0.99 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL667050 | 0.99 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL316743 | 0.99 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL22028284 | 0.95 | PDE5A (0.44) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL17274068 | 0.95 | PDE5A (0.44) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL5968262 | 0.94 | PDE5A (0.43) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545948-B2 | Identification of novel loci in asthma and methods of use thereof for the diagnosis and treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-02-10 | — | — | US | claimed |
| US-20260026967-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | GLAUKOS CORP (US) | 2026-01-29 | — | — | US | claimed |
| EP-4565206-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | Bausch + Lomb Ireland Limited (IE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024028816-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-02-08 | — | — | WO | claimed |
| WO-2024028815-A1 | OPHTHALMIC COMPOSITION COMPRISING AN ANTI-ALLERGEN AND A REDNESS REDUCTION AGENT | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-02-08 | — | — | WO | claimed |
| US-20220316008-A1 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-10-06 | — | — | US | claimed |
| EP-4028124-A1 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | The Children's Hospital Of Philadelphia (US) | 2022-07-20 | — | — | EP | claimed |
| EP-4743038-A1 | OCULAR IMPLANT WITH LEADING TIP, LEADING TIP AND METHOD OF DEPLOYMENT | Alcon Inc. (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260108386-A1 | OCULAR IMPLANT, OCULAR IMPLANT DELIVERY SYSTEM, AND METHODS OF DEPLOYING AN OCULAR IMPLANT | ALCON INC. (CH) | 2026-04-23 | — | — | US | disclosed |
| US-20260102283-A1 | PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME | GLAUKOS CORP (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4193907-B1 | INTRAOCULAR PHYSIOLOGICAL SENSOR | GLAUKOS CORP (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12599497-B2 | Implants with controlled drug delivery features and methods of using same | GLAUKOS CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4706607-A2 | INTRAOCULAR PHYSIOLOGICAL SENSOR | Glaukos Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4032563-A1 | CHITOSAN AND POLYETHYLENE GLYCOL COPOLYMERS AND METHODS AND DEVICES FOR USING SAME FOR SEALING A VASCULAR PUNCTURE | Access Closure, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-4028124-A1 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | The Children's Hospital Of Philadelphia (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11363951-B2 | Intraocular physiological sensor | GLAUKOS CORPORATION (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3581588-B1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING IGE-MEDIATED DISORDERS | XENCOR INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11318043-B2 | Bioresorbable ocular drug delivery device | DOSE MEDICAL CORPORATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220062193-A1 | METHOD OF DELIVERING AN ACTIVE COMPOUND AND DELIVERY DEVICE FOR USE IN THE SAME | WACKER CHEMIE AG (DE) | 2022-03-03 | — | — | US | disclosed |
| US-11253394-B2 | Controlled drug delivery ocular implants and methods of using same | DOSE MEDICAL CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062193-A1 | METHOD OF DELIVERING AN ACTIVE COMPOUND AND DELIVERY DEVICE FOR USE IN THE SAME | MMP8, CLPP, MMP7 | PDE5A 1166/4885ABCB11 45/4885CYSLTR2 1206/4885 |
| US-20260102283-A1 | PUNCTAL IMPLANTS, INSERTION SYSTEMS AND METHODS OF USING THE SAME | SSTR5, CFTR, STARD10 | PDE5A 789/4885ABCB11 198/4885CYSLTR2 1093/4885 |
| US-20260108386-A1 | OCULAR IMPLANT, OCULAR IMPLANT DELIVERY SYSTEM, AND METHODS OF DEPLOYING AN OCULAR IMPLANT | POU2F1, POU2F2, PDE6C | PDE5A 1383/4885ABCB11 247/4885CYSLTR2 4591/4885 |
| US-12545948-B2 | Identification of novel loci in asthma and methods of use thereof for the diagnosis and treatment of asthma | ADRA2B, ADRA1B, ADRB3 | PDE5A 70/4885ABCB11 2287/4885CYSLTR2 30/4885 |
| US-12599497-B2 | Implants with controlled drug delivery features and methods of using same | ABCB11, GHITM, SLC13A2 | PDE5A 189/4885ABCB11 1/4885CYSLTR2 1067/4885 |
| US-20260026967-A1 | MATERIALS AND METHODS FOR PUNCTAL PLUGS | GHRHR, TIMCC, GNRHR | PDE5A 1849/4885ABCB11 71/4885CYSLTR2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.